Edwards Lifesciences Corporation $EW Shares Sold by Credit Agricole S A

Key Points

• Credit Agricole S A significantly reduced its position in Edwards Lifesciences, cutting its holdings by 75.3% during the first quarter, now owning 79,161 shares valued at approximately $5.7 million.
• Edwards Lifesciences reported a quarterly earnings per share (EPS) of $0.67, beating estimates, with a revenue of $1.53 billion, an increase of 11.9% compared to the previous year.
• Recent analyst ratings suggest a positive outlook for the stock, with Wells Fargo raising its target price to $88 and several analysts issuing "buy" ratings, contributing to an average target price of $85.90.

Credit Agricole S A lowered its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 75.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 79,161 shares of the medical research company's stock after selling 241,662 shares during the period. Credit Agricole S A's holdings in Edwards Lifesciences were worth $5,738,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Prosperity Consulting Group LLC increased its position in shares of Edwards Lifesciences by 3.6% during the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after purchasing an additional 134 shares in the last quarter. Arlington Trust Co LLC increased its position in shares of Edwards Lifesciences by 1.2% during the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock worth $804,000 after purchasing an additional 135 shares in the last quarter. Valeo Financial Advisors LLC increased its position in shares of Edwards Lifesciences by 2.8% during the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock worth $372,000 after purchasing an additional 142 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Edwards Lifesciences by 9.3% during the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock worth $123,000 after purchasing an additional 145 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after purchasing an additional 145 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Citigroup reissued a "buy" rating and set a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. William Blair raised shares of Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Barclays upped their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, July 25th. Stifel Nicolaus upped their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "buy" rating in a report on Friday, July 25th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $85.90.

Edwards Lifesciences Price Performance

Shares of EW traded down $0.9090 during mid-day trading on Monday, hitting $80.9210. 4,393,047 shares of the company were exchanged, compared to its average volume of 4,195,043. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company has a 50 day moving average of $77.71 and a 200-day moving average of $74.79. The stock has a market cap of $47.51 billion, a price-to-earnings ratio of 11.64, a price-to-earnings-growth ratio of 3.95 and a beta of 1.08.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,584 shares of company stock worth $1,897,762. Insiders own 0.34% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.